Thus, in patients with operable NSCLC, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TMAs is of benefit for assessment of postoperative prognosis. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.